glp 1 agonist clinical trials Summaries of landmark with GLP-1 agonists GLP-1 single, dual, and triple

Community-reported research protocols (12 mg, 23 per week subcutaneously) are not validated by published clinical trials and are not recommendations from this wiki

Sequence-structure analysis of FAD-containing proteins

doi: 10.1016/j.toxicon.2021.09.002 Nixon, Samantha A., Robinson, Samuel D., Agwa, Akello J., Walker, Andrew A., Choudhary, Shivani, Touchard, Axel, Undheim, Eivind A.B., Robertson, Alan, Vetter, Irina, Schroeder, Christina I., Kotze, Andrew C., Herzig, Volker and King, Glenn F

Petrylak DP, Tangen CM, Hussain MH, Lara PNJ, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer